Nasdaq:CBUS
Cibus, Inc.
A biotech-enabled ingredient developer transforming the plant-based food market through proprietary fermentation and clean-label solutions.
Key Metrics
Investment Thesis
Bull Case
Investors might view Cibus as a high-risk, high-reward turnaround play given its substantial paid-in capital of $825.3M and significant cash reserves that could fuel an eventual exit from losses. The company operates in the rapidly expanding plant-based sector, positioning it to capture market share if management can successfully reduce its massive operating expense burden. Potential catalysts include new product launches leveraging its fermentation IP or a strategic acquisition that validates its $253.5M goodwill.
Bear Case
The stock is fundamentally compromised by consistent double-digit losses and an inability to cover its own operating costs, making it an unsafe investment for capital preservation. With revenue barely covering current liabilities and a retained earnings deficit exceeding $731M, the company appears to be consuming investor capital without delivering tangible returns. The disconnect between minimal revenue growth and exploding expenses indicates structural business model flaws that are unlikely to resolve under current management.
About Cibus, Inc.
Cibus Inc. is a specialty food ingredient developer focused on plant-based alternatives and functional ingredients for the global nutrition market. The company leverages proprietary fermentation technologies to create clean-label products that align with shifting consumer preferences toward sustainable and health-conscious lifestyles. Operating primarily in the North American specialty retail and foodservice sectors, Cibus aims to bridge the gap between traditional agriculture and modern biotechnology.
Analysis
Management Discussion
Recent financial performance reveals a critical divergence between revenue growth and profitability, with operating expenses skyrocketing to $262.7M while revenue only reached $4.3M in the latest period. The substantial non-cash adjustments of $224.9M and massive net loss suggest aggressive accounting or significant one-time write-downs are distorting the true economic picture of operations. Despite a healthy cash balance of $14.4M, the burn rate is unsustainable without a drastic pivot in cost structure or a major revenue inflection point.
Industry Overview
The global alternative protein industry is characterized by intense competition among biotech firms seeking to lower the cost of plant-based proteins while maintaining nutritional quality. Market participants face pressure to scale manufacturing rapidly, which often leads to high initial capital expenditures and significant operating losses before reaching profitability. Regulatory scrutiny on food safety and labeling for novel ingredients remains a constant challenge for companies navigating the transition from lab-scale fermentation to mass production.
Financial Statements
Income Statement
Balance Sheet
Cash Flow
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Revenue | $157.0K | $1.8M | $4.3M |
| Cost of Revenue | $0 | $0 | $0 |
| Gross Profit | $157.0K | $1.8M | $4.3M |
| Operating Expenses | $22.5M | $320.7M | $262.7M |
| Operating Income | $-22.4M | $-318.9M | $-258.4M |
| R&D | $11.6M | $42.4M | $50.4M |
| G&A | — | $28.9M | $30.8M |
| Marketing | $11.0M | — | — |
| Stock-Based Comp | $4.0M | $16.1M | $10.8M |
| D&A | $1.5M | $4.7M | $6.9M |
| Depreciation | — | $3.6M | $4.9M |
| Amortization | — | $1.1M | $1.8M |
| Other OpEx | $0 | $249.4M | $181.4M |
| Non-Operating Income | $5.5M | $-18.8M | $-24.3M |
| Interest Expense | $75.0K | — | — |
| Pre-Tax Income | $-16.9M | $-337.6M | $-282.7M |
| Income Tax | $0 | $-4.0K | $29.0K |
| Continuing Ops | $-16.9M | $-337.6M | $-282.7M |
| Discontinued Ops | $33.8M | $0 | $0 |
| Net Income | $16.9M | $-337.6M | $-282.7M |
| Minority Interest | $0 | $0 | $0 |
| Net to Common | $16.9M | $-337.6M | $-282.7M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Current Assets | $4.1M | $35.2M | $16.9M |
| Cash & Equivalents | $3.4M | $32.7M | $14.4M |
| Marketable Securities | $0 | — | — |
| Accounts Receivable | — | $530.0K | $1.0M |
| Prepaid Expenses | $606.0K | $2.0M | $1.5M |
| Other Current Assets | $99.0K | $0 | $0 |
| Long-Term Assets | $18.3M | $509.2M | $333.1M |
| PP&E (Net) | $4.5M | — | — |
| Intangibles | — | $35.4M | $33.6M |
| Goodwill | — | $434.9M | $253.5M |
| Operating Leases | $13.6M | $21.7M | $33.3M |
| Other LT Assets | $158.0K | $17.2M | $12.8M |
| Total Assets | $22.4M | $544.4M | $350.1M |
| Current Liabilities | $1.7M | $21.3M | $19.9M |
| Accounts Payable | $340.0K | $6.1M | $6.0M |
| Current Debt | — | $833.0K | $436.0K |
| Current Leases | $367.0K | $5.9M | $4.3M |
| Deferred Revenue | — | $1.2M | $932.0K |
| Other Current Liab | $782.0K | $5.5M | $6.0M |
| Long-Term Liabilities | $13.5M | $184.8M | $232.4M |
| Long-Term Debt | — | $536.0K | $226.0K |
| LT Operating Leases | $13.4M | $17.0M | $31.2M |
| Other LT Liab | $79.0K | $167.2M | $200.9M |
| Total Liabilities | $15.2M | $206.1M | $252.2M |
| Shareholders' Equity | $7.2M | $338.3M | $97.8M |
| Paid-In Capital | — | $775.0M | $825.3M |
| Retained Earnings | $-212.2M | $-479.8M | $-731.2M |
| AOCI | — | $8.0K | $15.0K |
| Total L&E | $22.4M | $544.4M | $350.1M |
| Metric | 2022 | 2023 | 2024 |
|---|---|---|---|
| Net Income (CFO) | $16.9M | $-337.6M | $-282.7M |
| Non-Cash Adjustments | $-33.7M | $295.2M | $224.9M |
| Working Capital Changes | $-2.6M | $-3.8M | $-193.0K |
| Cash from Operations | $-19.4M | $-46.2M | $-58.0M |
| Capital Expenditures | $1.5M | $4.3M | $808.0K |
| Cash from Investing | $-1.5M | $55.1M | $-808.0K |
| Cash from Financing | $10.0M | $20.3M | $40.6M |
| FX Effect | $0 | $3.0K | $-13.0K |
| Net Change in Cash | $-10.9M | $29.2M | $-18.3M |
| Beginning Cash | $14.4M | $3.5M | $32.7M |
| Ending Cash | $3.5M | $32.7M | $14.4M |
Frequently Asked Questions
How does Cibus, Inc. make money?
The company's revenue is driven by its core development of probiotic-rich functional ingredients, plant-based meat analogues, and specialized nutrition additives for major consumer packaged goods manufacturers. Financials indicate a heavy reliance on high-value contract research and development services alongside the sale of finished specialty ingredient batches to premium retailers.
What are the main risks for CBUS?
The company faces severe profitability challenges evidenced by a net loss of $282.7M in 2024 and negligible revenue growth, raising concerns about cash runway and operational scalability. Heavy dependence on non-operating financing cash flows of $40.6M highlights an inability to generate sufficient organic operating cash flow to fund its own growth. Significant intangible asset concentration with $253.5M in goodwill creates vulnerability to impairment charges if market sentiment shifts or acquisition synergies fail to materialize.
What is CBUS's competitive advantage?
Cibus possesses a robust intellectual property portfolio centered on proprietary fermentation strains that offer unique functional properties not easily replicated by competitors. The company benefits from strong partnerships with major foodservice distributors and retail chains seeking scalable, sustainable protein sources for their product lines. Its lean capital structure relative to its massive goodwill suggests successful past acquisitions or significant brand valuation retained from the biotech sector.
Related Companies
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.